KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Lin, Yu Lin ^a,b   Liau, Jau Yu ^a   Yu, Shan Chi ^a   Ou, Da Liang ^a,b   Lin, Liang In ^a,b   Tseng, Li Hui ^a   Chang, Yih Leong ^a,b   Yeh, Kun Huei ^a,b   Cheng, Ann Lii ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DOXORUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; IRINOTECAN; K RAS PROTEIN; MESSENGER RNA; OXALIPLATIN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CELL LEVEL; CELL VIABILITY; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG SENSITIVITY; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; GENE VECTOR; HUMAN; HUMAN CELL; IC 50; KRAS GENE; PREDICTIVE VALUE; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TREATMENT RESPONSE; TUMOR GENE; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL SURVIVAL; COLONIC NEOPLASMS; DNA-BINDING PROTEINS; ENDONUCLEASES; FLUOROURACIL; HUMANS; MUTATION; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84870376365     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050701     Document Type: Article

References (28)

1. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E, (1994) Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94: 703-708.
2. Van Triest B, Pinedo HM, van Hensbergen Y, Smid K, Telleman F, et al. (1999) Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines. Clin cancer Res 5: 643-654.
3. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
4. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, et al. (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995.
5. Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, et al. (2009) Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137: 821-834.
6. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, et al. (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137: 835-848.
7. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, et al. (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663-671.
8. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, et al. (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697-4705.
9. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417.
10. Sugimoto Y, Tsukahara S, Oh-hara T, Isoe T, Tsuruo T, (1990) Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res 50: 6925-6930.
11. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, et al. (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229-237.
12. Esteller M, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, et al. (2000) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 60: 2368-2371.
13. Eden S, Cedar H, (1994) Role of DNA methylation in the regulation of transcription. Curr Opin Genet Dev 4: 255-259.
14. Chen HY, Shao CJ, Chen FR, Kwan AL, Chen ZP, (2010) Role of ERCC1 promoter hypermethylation in drug resistance to cisplatin in human gliomas. Int J Cancer 126: 1944-1954.
15. Trahey M, McCormick F, (1987) A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science 238: 542-545.
16. Bos JL, (1989) ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689.
17. Ou DL, Shen YC, Yu SL, Chen KF, Yeh PY, et al. (2010) Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 70: 9309-9318.
18. Golding SE, Rosenberg E, Neill S, Dent P, Povirk LF, et al. (2007) Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Res 67: 1046-1053.
19. Squatrito M, Holland EC, (2011) DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance. Cancer Res 71: 5945-5949.
20. Lee KB, Parker RJ, Bohr V, Cornelison T, Reed E, (1993) Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis 14: 2177-2180.
21. Sancar A, (1994) Mechanisms of DNA excision repair. Science 266: 1954-1956.
22. Zhen W, Link CJ Jr, OConnor PM, Reed E, Parker R, et al. (1992) Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines. Mol Cell Biol 12: 3689-3698.
23. Jones JC, Zhen WP, Reed E, Parker RJ, Sancar A, et al. (1991) Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells. J Biol Chem 266: 7101-7107.
24. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, et al. (1992) ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84: 1512-1517.
25. Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, et al. (2005) High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 11: 2215-2221.
26. Takenaka T, Yoshino I, Kouso H, Ohba T, Yohena T, et al. (2007) Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int J Cancer 121: 895-900.
27. Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Albiol S, et al. (2007) Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 18: 522-528.
28. Winder T, Mundlein A, Rhomberg S, Dirschmid K, Hartmann BL, et al. (2009) Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer. Oncol Rep 21: 1283-1287.